Loading clinical trials...
Loading clinical trials...
A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Novartis
East Hanover, New Jersey, United States
Investigative Centers, Germany
Start Date
March 1, 2005
Primary Completion Date
July 1, 2006
Completion Date
July 1, 2006
Last Updated
November 8, 2011
976
ACTUAL participants
Aliskiren
DRUG
Lead Sponsor
Novartis
NCT02417740
NCT07073820
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480265